Lastly, miR-185 and miR-342 have been shown to control lipogenesis and cholesterogenesis by inhibiting SREBP-1 and -2 expression and downregulating their target genes (FASN and HMG-CoA reductase) in prostate cancer [105]. The gene discussed is HMGCR; the disease is Familial prostate cancer.